AMLSG 30-18 (#752)
Laufzeit: 01.01.2020 - 31.12.2040
Kurzfassung
Randomized phase III study of standard intensive chemotherapy versus intensive chemotherapy with CPX-351 in adult patients with newly diagnosed AML and intermediate or adverse genetics
Laufzeit: 01.01.2020 - 31.12.2040
Randomized phase III study of standard intensive chemotherapy versus intensive chemotherapy with CPX-351 in adult patients with newly diagnosed AML and intermediate or adverse genetics
